Table 1 Comparison of baseline variables between FN cases receiving antimicrobial therapy recommended by the ASP and those receiving other antimicrobial regimens (non-ASP)
Variables | ASP group N = 162 | Non-ASP group N = 145 | PS adjusted, P-value |
|---|---|---|---|
Age, mean ± SD, years | 41.8 ± 14.5 | 39.4 ± 13.8 | 0.07 |
Female sex (%) | 80 (49.4) | 68 (46.9) | 0.76 |
Clinical comorbidity (%) | 33 (20.4) | 43 (29.6) | 0.31 |
Type of neoplastic disease | 0.71 | ||
- Haematological (%) | 128 (79.0) | 114 (78.6) | |
- Solid tumour (%) | 34 (21.0) | 31 (21.4) | |
Chemotherapy regimens | 0.95 | ||
- High-dose (%) | 88 (54.3) | 76 (52.4) | |
- Standard-dose (%) | 74 (45.7) | 69 (47.6) | |
Relapsing underlying disease status (%) | 77 (47.5) | 78 (53.8) | 0.30 |
Antibiotic use in the previous 30 days (%) | 49 (30.2) | 61 (42.0) | 0.15 |
Hospitalisation in the previous 30 days (%) | 59 (36.4) | 61 (42.0) | 0.59 |
Median ANC at the time of diagnosis of FN (IQR), cells/mm3 | 175 (60–340) | 100 (40–260) | 0.61 |
ANC < 100 cells/mm3 at the time of FN (%) | 62 (38.3) | 68 (46.9) | 0.78 |
Nosocomial-acquired FN (%) | 127 (78.4) | 123 (84.8) | 0.83 |
Hypotension at the time of diagnosis of FN (%) | 4 (2.5) | 27 (18.6) | 0.46 |
Diarrhoea at the time of diagnosis of FN (%) | 14 (8.6) | 48 (33.1) | 0.10 |
Perianal pain at the time of diagnosis of FN (%) | 6 (3.7) | 26 (17.9) | 0.67 |
Suspected source of oral cavity infections (%) | 3 (1.8) | 12 (8.3) | 0.85 |
Cutaneous manifestations of infection (%) | 8 (5.0) | 42 (28.9) | 0.92 |
High-risk MASCC score (%) | 35 (21.6) | 48 (33.1) | 0.95 |